How to successfully commercialise microbiome-based diagnostics
In this Med-tech Innovation News article, Andrew Thomson, Brian Carpenter and Robert Broadnax explore key drivers of adoption of microbiome-based diagnostics,...
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
We are rare disease specialists.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
- 50+Rare disease areas covered
- 300+Rare disease engagements since 2017
Our rare disease offerings span across the product lifecycle.
- Early developmentDiscover
- Early PMA assessment
- Pipeline opportunity assessment
- Diagnostics & screening
- Incentives review
- Licensing / commercially reasonable efforts disputes
- Late developmentDevelop
- Market access & evidence generation strateg
- Payer value proposition
- Patient finding
- Landscape assessment & policy shaping
- LaunchDeliver
- Launch pricing strategy
- Payer negotiation
- Launch excellence
- Stakeholder engagement
- Competitive simulations
- Regulatory and P&R policies
- Uptake and diffusion
- Life cycle & LOEDefend
- Indication & geographic expansion
- Competitor response strategies
- Price/access/uptake benchmarking and assessments
- LOE strategies
Engagements
- 01Understanding and segmenting a rare disease marketClient Issue Our client sought to develop a better understanding of the market for a rare disease, including patient diversity and treatment, in anticipation...View engagement